2018
DOI: 10.1111/bjh.15573
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: SummaryAvatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6‐month, multicentre, randomised, double‐blind, parallel‐group Phase 3 study, with an open‐label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day) in adults with chronic immune thrombocytopenia (ITP) and a platelet count <30 × 109/l (ClinicalTrials.gov identifier NCT01438840). The primary endpoint was the cumulative number of weeks of platelet response (platelet count ≥50 × 109/l) without r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

2
138
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 133 publications
(140 citation statements)
references
References 19 publications
(38 reference statements)
2
138
0
Order By: Relevance
“…Potentially, it is not only highly effective but also would be taken daily by mouth and does not have dietary restrictions. As reported initially in 2014 (Bussel et al , ) and in the phase III study in this issue of the British Journal of Haematology (Jurczak et al , ), it would appear to be similar in efficacy and safety to eltrombopag and romiplostim. In the phase II study reported by Bussel et al () and the current study (Jurczak et al , ), the efficacy was high.…”
mentioning
confidence: 59%
See 3 more Smart Citations
“…Potentially, it is not only highly effective but also would be taken daily by mouth and does not have dietary restrictions. As reported initially in 2014 (Bussel et al , ) and in the phase III study in this issue of the British Journal of Haematology (Jurczak et al , ), it would appear to be similar in efficacy and safety to eltrombopag and romiplostim. In the phase II study reported by Bussel et al () and the current study (Jurczak et al , ), the efficacy was high.…”
mentioning
confidence: 59%
“…As reported initially in 2014 (Bussel et al , ) and in the phase III study in this issue of the British Journal of Haematology (Jurczak et al , ), it would appear to be similar in efficacy and safety to eltrombopag and romiplostim. In the phase II study reported by Bussel et al () and the current study (Jurczak et al , ), the efficacy was high. The current study identified 4 thromboembolic/cardiovascular in just over 40 patients; this is higher than the 6% or so seen in long‐term studies of eltrombopag and romiplostim (Kuter et al , ; Wong et al , ).…”
mentioning
confidence: 59%
See 2 more Smart Citations
“…Overall, the drug was well tolerated with no major serious adverse events. 53 In a case report of a patient undergoing treatment for hepatocellular carcinoma, lusutrombopag was administered on two occasions 4 months apart. On both occasions, a good response to the platelet count was noted and there were no adverse events that were documented.…”
Section: Other Safety Issuesmentioning
confidence: 99%